Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2017 pubmed 39 citations

High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction.

Thummasorn. Savitree S; Shinlapawittayatorn. Krekwit K; Chattipakorn. Siriporn C SC; Chattipakorn. Nipon N

Key Findings

  • A 252 µg/kg dose of Humanin analogue during ischemia cut arrhythmias and infarct size in rats
  • The same high dose improved mitochondrial function and left‑ventricular performance
  • Lower doses (84 and 168 µg/kg) were ineffective, and timing after ischemia onset mattered

Practical Outcomes

  • The result hints that Humanin could protect the heart if delivered at the right dose and moment, but it’s currently only proven in animal studies with IV infusion during a heart attack. Biohackers should wait for human safety and dosing data before trying any self‑administration.

Summary

In rats, a high dose of a Humanin‑like peptide given while the heart was blocked reduced heart rhythm problems, heart tissue damage, and helped the heart's power plants (mitochondria) work better. Lower doses didn’t help, and the benefit only showed when the peptide was given during the blockage, not after.

Abstract

Although the gold standard treatment for acute myocardial infarction is reperfusion therapy, reperfusion itself can cause myocardial damage via induction of cardiac mitochondrial dysfunction. This can lead to increased myocardial infarct size, arrhythmias, and left ventricular (LV) dysfunction. Recently, a newly discovered peptide, Humanin, has been shown to exert several beneficial effects including antioxidative and antiapoptosis effects. We recently reported that a Humanin analogue (HNG, 84 μg/kg) given prior to cardiac ischemia exerted cardioprotection against I/R injury, but failed to do so when it was given after ischemia was induced. However, in a clinical setting, patients can only be treated after the onset of ischemia. In this study, we investigated the potential benefit of various doses of HNG therapy (84, 168, 252 μg/kg) against myocardial I/R injury when applied during ischemia on cardiac arrhythmia, myocardial infarct size, cardiac mitochondrial function, and LV function. Myocardial I/R injury was induced in rats by 30-minute left anterior descending coronary artery occlusion, followed by 120-minute of reperfusion. HNG at the different doses were given intravenously at 15 minutes after ischemic onset and also at the onset of reperfusion. HNG (252 μg/kg) applied during the ischemic period not only increased HN levels in the damaged myocardium, but also significantly decreased cardiac arrhythmia, myocardial infarct size, cardiac mitochondrial dysfunction, and left ventricular dysfunction. These benefits were mediated through the attenuation of cardiac mitochondrial dysfunction. High-dose HN applied during ischemia in rats could exert cardioprotection against I/R injury-induced mitochondrial dysfunction.

Study Information

Provider

pubmed

Year

2017

Date

2017-10-01T00:00:00.000Z

DOI

10.1111/1755-5922.12289

Citations

39

References

40